Physician profile
Arati Joshi
NPI 1437251246
$3,552.74
in general payments reported to CMS, 2019-2025
30 companies · $657 in 2025
The $657 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.68 · 2021: $277 · 2022: $454 · 2023: $1,187 · 2024: $952 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $668.07 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Shield Therapeutics INC | $510.92 | 2023-2025 | Accrufer |
| Lilly USA, LLC | $283.29 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Dexcom, INC. | $210.43 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $195.73 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $185.02 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $166.45 | 2022-2025 | Veozah |
| Pfizer INC. | $149.20 | 2022-2025 | |
| Exact Sciences Corporation | $138.02 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.22 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $111.85 | 2022-2024 | |
| Esperion Therapeutics, INC. | $107.12 | 2021-2025 | Nexletol |
| Amgen INC. | $104.07 | 2021-2024 | Repatha, Otezla, Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $81.79 | 2022 | |
| Biogen, INC. | $64.40 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $61.26 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $58.34 | 2022-2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $47.54 | 2024 | Trintellix |
| Edwards Lifesciences Corporation | $47.15 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Silk Road Medical, INC. | $41.61 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Kowa Pharmaceuticals America, INC. | $35.26 | 2023 | Seglentis |
| Dynavax Technologies Corporation | $28.73 | 2023 | Heplisav-B |
| Neurocrine Biosciences, INC. | $25.25 | 2025 | |
| Horizon Therapeutics Plc | $21.50 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $21.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.91 | 2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $14.14 | 2025 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2023 | Xifaxan, Trulance |
| Evofem Biosciences, INC. | $4.05 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arati Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.